Seek Returns

NBIX vs. ZTS: Neurocrine Biosciences vs. Zoetis Stock Comparison

How do Neurocrine Biosciences (NBIX) and Zoetis (ZTS) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Neurocrine Biosciences (NBIX) and Zoetis (ZTS) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but NBIX is classified in Biotechnology while ZTS is classified in Pharmaceuticals.

Company profile comparison for Neurocrine Biosciences (NBIX) and Zoetis (ZTS)
Profile ItemNBIXZTS
NameNeurocrine Biosciences, Inc.Zoetis Inc. Class A Common Stock
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnologyPharmaceuticals
GICS Sub-IndustryBiotechnologyPharmaceuticals
Market Capitalization16.66 billion USD32.26 billion USD
CurrencyUSDUSD
ExchangeNasdaqNYSE
Listing DateMay 23, 1996February 1, 2013
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

NBIX
ZTS
GSPC
Loading price history…
Neurocrine Biosciences (NBIX) vs. Zoetis (ZTS), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Neurocrine Biosciences (NBIX) and Zoetis (ZTS). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Neurocrine Biosciences (NBIX) and Zoetis (ZTS). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Neurocrine Biosciences (NBIX) and Zoetis (ZTS)
MetricNBIXZTS
Total Return (1Y)9.40%-30.10%
Total Return (3Y, Annualized)14.12%-20.42%
Total Return (5Y, Annualized)12.61%-16.87%

Risk Profile

Drawdown History

NBIX
ZTS
GSPC
Loading price history…
Neurocrine Biosciences (NBIX) vs. Zoetis (ZTS), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Neurocrine Biosciences (NBIX) and Zoetis (ZTS). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Neurocrine Biosciences (NBIX) and Zoetis (ZTS)
MetricNBIXZTS
Volatility (1Y, Annualized)35.05%38.23%
Beta (5Y)0.290.66
Max Drawdown (5Y)-42.89%-70.45%
Avg. Volume (3M)1.31M4.65M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
NBIX and ZTS are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Neurocrine Biosciences (NBIX) and Zoetis (ZTS)
MetricNBIXZTS
Sharpe Ratio (1Y)0.15-0.90
Sortino Ratio (1Y)0.22-1.10

Profitability

ROE (TTM)

Both Neurocrine Biosciences (NBIX) at 20.42% and Zoetis (ZTS) at 57.63% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

NBIX

Pharmaceuticals, Biotechnology & Life Sciences industry group

20.42%

Max
109.18%
NBIX
20.42%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

57.63%

Max
109.18%
ZTS
57.63%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Neurocrine Biosciences (NBIX) vs. Zoetis (ZTS): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Both Neurocrine Biosciences (NBIX) at 18.98% and Zoetis (ZTS) at 26.41% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

NBIX

Pharmaceuticals, Biotechnology & Life Sciences industry group

18.98%

NBIX
18.98%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

26.41%

ZTS
26.41%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Neurocrine Biosciences (NBIX) vs. Zoetis (ZTS): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Neurocrine Biosciences (NBIX) at 31.98% and Zoetis (ZTS) at 38.19% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

NBIX

Pharmaceuticals, Biotechnology & Life Sciences industry group

31.98%

Max
83.12%
NBIX
31.98%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

38.19%

Max
83.12%
ZTS
38.19%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Neurocrine Biosciences (NBIX) vs. Zoetis (ZTS): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Neurocrine Biosciences (NBIX) and Zoetis (ZTS)
MetricNBIXZTS
ROE (TTM)20.42%57.63%
ROA (TTM)12.45%14.87%
Net Margin (TTM)18.98%26.41%
Operating Margin (TTM)31.98%38.19%
Gross Margin (TTM)64.67%71.65%

Growth

Revenue Growth

Both Neurocrine Biosciences (NBIX) at 21.45% and Zoetis (ZTS) at 2.28% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Loading chart…
Neurocrine Biosciences (NBIX) vs. Zoetis (ZTS): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both Neurocrine Biosciences (NBIX) at 41.95% and Zoetis (ZTS) at 10.05% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Loading chart…
Neurocrine Biosciences (NBIX) vs. Zoetis (ZTS): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Neurocrine Biosciences (NBIX) and Zoetis (ZTS)
MetricNBIXZTS
Revenue Growth (YoY)21.45%2.28%
Revenue Growth (3Y CAGR)24.32%5.42%
EPS Growth (YoY)41.95%10.05%
EPS Growth (3Y CAGR)44.12%10.27%

Financial Strength

Current Ratio (MRQ)

Both Neurocrine Biosciences (NBIX) at 2.04 and Zoetis (ZTS) at 2.35 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

NBIX

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.04

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
NBIX
2.04
Min
0.10

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.35

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
ZTS
2.35
Min
0.10
Loading chart…
Neurocrine Biosciences (NBIX) vs. Zoetis (ZTS): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Neurocrine Biosciences (NBIX) at 0.12 is near its industry mid-range for debt-to-equity ratio, while Zoetis (ZTS) at 2.80 sits above its benchmark range, pointing to a heavier debt load relative to equity.

NBIX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.12

Max
1.42
Q3
0.65
Median
0.15
NBIX
0.12
Q1
0.02
Min
0.00

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.80

ZTS
2.80
Max
1.42
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Neurocrine Biosciences (NBIX) vs. Zoetis (ZTS): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Neurocrine Biosciences (NBIX) and Zoetis (ZTS)
MetricNBIXZTS
Current Ratio (MRQ)2.042.35
Debt / Equity (MRQ)0.122.80
Net Debt / EBITDA-0.271.92

Dividends

Dividend Yield (TTM)

Neurocrine Biosciences (NBIX) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Zoetis (ZTS) reports a yield of 2.55%, ranking against industry peers normally.

NBIX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

NBIX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.55%

ZTS
2.55%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Neurocrine Biosciences (NBIX) vs. Zoetis (ZTS): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neurocrine Biosciences (NBIX) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Zoetis (ZTS) reports a payout of 35.24%, ranking against industry peers normally.

NBIX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

NBIX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

35.24%

ZTS
35.24%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Neurocrine Biosciences (NBIX) vs. Zoetis (ZTS): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Neurocrine Biosciences (NBIX) and Zoetis (ZTS)
MetricNBIXZTS
Dividend Yield (TTM)0.00%2.55%
Dividend Payout Ratio (TTM)0.00%35.24%

Valuation

P/E Ratio (TTM)

Both Neurocrine Biosciences (NBIX) at 24.43 and Zoetis (ZTS) at 13.50 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

NBIX

Pharmaceuticals, Biotechnology & Life Sciences industry group

24.43

Max
85.34
Q3
43.46
Median
26.69
NBIX
24.43
Q1
13.30
Min
0.07

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.50

Max
85.34
Q3
43.46
Median
26.69
ZTS
13.50
Q1
13.30
Min
0.07
Loading chart…
Neurocrine Biosciences (NBIX) vs. Zoetis (ZTS): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Neurocrine Biosciences (NBIX) at 4.50 and Zoetis (ZTS) at 3.40 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

NBIX

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.50

Max
58.18
Q3
25.77
Median
7.30
NBIX
4.50
Q1
3.01
Min
0.01

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.40

Max
58.18
Q3
25.77
Median
7.30
ZTS
3.40
Q1
3.01
Min
0.01
Loading chart…
Neurocrine Biosciences (NBIX) vs. Zoetis (ZTS): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Neurocrine Biosciences (NBIX) at 4.30 is valued about in line with its industry on P/B ratio, while Zoetis (ZTS) at 9.80 carries an above-peer premium to book — ZTS is pricier on assets.

NBIX

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.30

Max
13.53
Q3
6.54
NBIX
4.30
Median
3.25
Q1
1.69
Min
-5.59

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.80

Max
13.53
ZTS
9.80
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
Neurocrine Biosciences (NBIX) vs. Zoetis (ZTS): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Neurocrine Biosciences (NBIX) and Zoetis (ZTS)
MetricNBIXZTS
P/E Ratio (TTM)24.4313.50
P/S Ratio (TTM)4.503.40
P/B Ratio (MRQ)4.309.80
Free Cash Flow Yield (TTM)6.11%6.36%